{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:56:35Z","timestamp":1785495395971,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":100,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101214","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:38:34Z","timestamp":1776011914000},"page":"101214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The complex landscape of non-coding RNAs in olaparib response and resistance"],"prefix":"10.1016","volume":"47","author":[{"given":"Fatemeh","family":"Tahamipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Ghahghaei-Nezamabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-499X","authenticated-orcid":false,"given":"Soudeh","family":"Ghafouri-Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101214_bib0001","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101214_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101214_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101214_bib0006","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846263","article-title":"Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments","volume":"19","author":"Liao","year":"2018","journal-title":"EMBo Rep."},{"key":"10.1016\/j.ctarc.2026.101214_bib0007","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.4103\/ijc.IJC_53_21","article-title":"A review on mechanisms of resistance to PARP inhibitors","volume":"59","author":"Desai","year":"2022","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101214_bib0008","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101214_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2025.11.038","article-title":"ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer","author":"Huang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/fon-2020-0989","article-title":"DNA damage response alterations in gastric cancer: knocking down a new wall","volume":"17","author":"Ricci","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070677","article-title":"Hacking pancreatic cancer: present and future of personalized medicine","volume":"14","author":"Di Federico","year":"2021","journal-title":"Pharmaceuticals. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101214_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040907","article-title":"PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what's now, what's new, and what's coming?","volume":"14","author":"Marchetti","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101214_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2026.101214_bib0014","article-title":"Elacestrant in metastatic breast cancer: current advancements and future perspectives","author":"Sahin","year":"2025","journal-title":"Expert. Rev. AntiCancer Ther."},{"key":"10.1016\/j.ctarc.2026.101214_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17425255.2022.2072727","article-title":"Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0016","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12032-025-03171-9","article-title":"Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy","volume":"43","author":"Tajik","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0017","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1186\/s40001-025-03045-w","article-title":"Circular RNAs: key regulators of paclitaxel sensitivity and resistance in cancer","volume":"30","author":"Tajik","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0018","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s11033-025-10908-2","article-title":"CircRNAs: emerging players in tyrosine kinase inhibitor resistance mechanisms in solid tumors","volume":"52","author":"Soleimani","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ctarc.2026.101214_bib0019","article-title":"Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia","volume":"24","author":"Talemi","year":"2025","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.ctarc.2026.101214_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv108","article-title":"Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers","volume":"107","author":"Liu","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101214_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100987","article-title":"MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2\/\u03b2-catenin in serous ovarian cancers","volume":"14","author":"Sun","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13058-023-01615-6","article-title":"Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer","volume":"25","author":"Mani","year":"2023","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13058-023-01663-y","article-title":"Transcriptionally regulated miR-26a-5p may act as BRCAness in triple-negative breast cancer","volume":"25","author":"Zhang","year":"2023","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0024","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molcel.2010.12.005","article-title":"miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors","volume":"41","author":"Moskwa","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ctarc.2026.101214_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13578-023-01151-y","article-title":"MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer","volume":"13","author":"Bustos","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ctarc.2026.101214_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100867","article-title":"Uncovering miRNA-mRNA regulatory networks related to olaparib resistance and resensitization of BRCA2(MUT) ovarian cancer PEO1-OR cells with the ATR\/CHK1 pathway inhibitors","volume":"13","author":"Biega\u0142a","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2026.101214_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13046-019-1490-7","article-title":"MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1","volume":"39","author":"Vescarelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0028","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1535370221994077","article-title":"Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting","volume":"246","author":"Zhong","year":"2021","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.ctarc.2026.101214_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030519","article-title":"MiR-200c-3p contrasts PD-L1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of \u03b2-catenin and c-myc","volume":"10","author":"Anastasiadou","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2026.101214_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-020-0844-0","article-title":"MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC","volume":"13","author":"Sun","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0031","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1096\/fj.201903045RR","article-title":"Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p\/BRCA1 signaling","volume":"34","author":"Zhao","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.ctarc.2026.101214_bib0032","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1389202923666220527114108","article-title":"Construction of PARPi resistance-related competing endogenous RNA network","volume":"23","author":"Kong","year":"2022","journal-title":"Curr. Genomics."},{"key":"10.1016\/j.ctarc.2026.101214_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70244","article-title":"HIF-1\u03b1-induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP-ribosylation","volume":"15","author":"Wu","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101214_bib0034","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2767-9764.CRC-23-0089","article-title":"Targeting MALAT1 augments sensitivity to PARP inhibition by impairing homologous recombination in prostate cancer","volume":"3","author":"Yadav","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ctarc.2026.101214_bib0035","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/0008-5472.CAN-13-3159","article-title":"PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer","volume":"74","author":"Prensner","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217192","article-title":"Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer","volume":"602","author":"Wu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2026.101214_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184617","article-title":"Let-7i reduces aggressive phenotype and induces BRCAness in ovarian cancer cells","volume":"13","author":"Chirshev","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101214_bib0038","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.omto.2020.10.010","article-title":"lncRNA DUXAP8 facilitates multiple malignant phenotypes and resistance to PARP inhibitor in HCC via upregulating FOXM1","volume":"19","author":"Hu","year":"2020","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.ctarc.2026.101214_bib0039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-025-01957-z","article-title":"CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p\/NGFR pathway","volume":"19","author":"Chen","year":"2026","journal-title":"J. Ovarian. Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-022-02343-z","article-title":"Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p\/RPN6 axis in pancreatic ductal adenocarcinoma","volume":"41","author":"Chen","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101214_bib0041","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1186\/s12885-025-14568-0","article-title":"Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866","volume":"25","author":"Sha","year":"2025","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101214_bib0042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12672-025-02048-7","article-title":"Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells","volume":"16","author":"Wang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ctarc.2026.101214_bib0043","article-title":"PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer","volume":"7","author":"Song","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101214_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122690","article-title":"The PARP inhibitor Olaparib modulates the transcriptional regulatory networks of long non-coding RNAs during vasculogenic mimicry","volume":"9","author":"Fern\u00e1ndez-Cort\u00e9s","year":"2020","journal-title":"Cells"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:42:53Z","timestamp":1780918973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":44,"alternative-id":["S2468294226001255"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101214","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The complex landscape of non-coding RNAs in olaparib response and resistance","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101214"}}